These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37356987)

  • 21. Unraveling the Mystery of Gray Zone Lymphoma in Human Immunodeficiency Virus-Seropositive Patients: Two Cases.
    Ahluwalia A; Bondili L; Salamera J; Cholankeril M
    J Hematol; 2020 Dec; 9(4):132-136. PubMed ID: 33224393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and prognostic analysis of 98 cases of relapsed/refractory diffuse large B-cell lymphoma treated with second-line regimens].
    Zhang MC; Qian Y; Hao J; Liu ZY; Zhao WL; Wang L
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):511-516. PubMed ID: 28655095
    [No Abstract]   [Full Text] [Related]  

  • 23. Mutational landscape of gray zone lymphoma.
    Sarkozy C; Hung SS; Chavez EA; Duns G; Takata K; Chong LC; Aoki T; Jiang A; Miyata-Takata T; Telenius A; Slack GW; Molina TJ; Ben-Neriah S; Farinha P; Dartigues P; Damotte D; Mottok A; Salles GA; Casasnovas RO; Savage KJ; Laurent C; Scott DW; Traverse-Glehen A; Steidl C
    Blood; 2021 Apr; 137(13):1765-1776. PubMed ID: 32961552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.
    Pilichowska M; Pittaluga S; Ferry JA; Hemminger J; Chang H; Kanakry JA; Sehn LH; Feldman T; Abramson JS; Kritharis A; Hernandez-Ilizaliturri FJ; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA; Jagadeesh D; Woda B; Gupta GK; Gascoyne RD; Jaffe ES; Evens AM
    Blood Adv; 2017 Dec; 1(26):2600-2609. PubMed ID: 29296913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.
    Hojo N; Nagasaki M; Mihara Y
    World J Clin Cases; 2022 Jun; 10(17):5708-5716. PubMed ID: 35979119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.
    Sarkozy C; Copie-Bergman C; Damotte D; Ben-Neriah S; Burroni B; Cornillon J; Lemal R; Golfier C; Fabiani B; Chassagne-Clément C; Parrens M; Herbaux C; Xerri L; Bossard C; Laurent C; Cheminant M; Cartron G; Cabecadas J; Molina T; Salles G; Steidl C; Ghesquières H; Mottok A; Traverse-Glehen A
    Am J Surg Pathol; 2019 Mar; 43(3):341-351. PubMed ID: 30540571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression profiling of gray zone lymphoma.
    Sarkozy C; Chong L; Takata K; Chavez EA; Miyata-Takata T; Duns G; Telenius A; Boyle M; Slack GW; Laurent C; Farinha P; Molina TJ; Copie-Bergman C; Damotte D; Salles GA; Mottok A; Savage KJ; Scott DW; Traverse-Glehen A; Steidl C
    Blood Adv; 2020 Jun; 4(11):2523-2535. PubMed ID: 32516416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission.
    Terao T; Yuda J; Yamauchi N; Guo YM; Shimada K; Sugano M; Ishii G; Minami Y
    Mol Clin Oncol; 2021 Jun; 14(6):125. PubMed ID: 33936598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric gray zone lymphoma according to the 2022 WHO classification: An Italian cohort study.
    Restivo GA; Farruggia P; Pillon M; Mascarin M; Elia C; Recupero S; Muggeo P; Cagnazzo C; Onofrillo D; Mura R; Furfari I; Trizzino A; Bertolini P; Sala A; De Santis R; Galimberti D; Schiavello E; Carraro E;
    Pediatr Blood Cancer; 2023 May; ():e30481. PubMed ID: 37254478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gray-zone lymphoma. Examples of rare clinical manifestation.
    Misyurina AE; Kravchenko SK; Mangasarova YK; Magomedova AU; Kovrigina AM; Shimanovskaya LT; Fastova EA; Misyurin VA; Model SV; Chebotarev DI; Kostina IE; Savchenko VG
    Ter Arkh; 2019 May; 91(4):107-113. PubMed ID: 31094484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dose-intensive immunochemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of 29 newly diagnosed young patients with medium/high risk diffuse large B-cell lymphoma].
    Yi S; Liu W; Lyu R; Li Z; Xu Y; Sui W; Huang W; Wang T; Deng S; Liu H; Fu M; Zou D; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):546-50. PubMed ID: 24985182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].
    Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Ma XL; Zhang YH
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):748-753. PubMed ID: 29050112
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical Analysis of 153 Cases of Refractory/Relapsed Diffuse Large B-cell Lymphoma].
    Zou DD; Guo B; Yin P; Tian Y; Zhu HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):120-125. PubMed ID: 28245387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens.
    Villela L; López-Guillermo A; Montoto S; Rives S; Bosch F; Perales M; Ferrer A; Esteve J; Colomo L; Campo E; Montserrat E
    Cancer; 2001 Apr; 91(8):1557-62. PubMed ID: 11301405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
    Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
    Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.
    Traverse-Glehen A; Pittaluga S; Gaulard P; Sorbara L; Alonso MA; Raffeld M; Jaffe ES
    Am J Surg Pathol; 2005 Nov; 29(11):1411-21. PubMed ID: 16224207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
    Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
    Gibson SE; Dojcinov S; Dotlic S; Hartmann S; Hsi ED; Klimkowska M; Melle F; Pileri SA; Ramsower CA; Rech K; Rimsza LM; Rodriguez-Pinilla SM; Tousseyn TA; de Jong D; Sabattini E
    Virchows Arch; 2023 Dec; 483(6):733-749. PubMed ID: 37530791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.